- Pregnancy technology company HeraMED (HMD) enters a trading halt while it considers, plans and executes a capital raising
- The company will remain in the halt until October 18 or when an announcement is made released, whichever occurs first
- On Septeber 13, HeraMED received interim results from its paid pilot agreement with Obstetrix Medical Group which is testing the HeraCARE platform
- The interim results were positive with an 89 per cent overall positive patient adherence rate achieved
- Shares in HeraMED last traded at 19 cents on October 12
Pregnancy technology company HeraMED (HMD) has entered a trading halt while it considers, plans and executes a capital raising.
The company will remain in the halt until October 18 or when an announcement is released, whichever occurs first.
HeraMED is yet to disclose how much it intends to raise or what it will use the funds for once received.
On September 13, HeraMED received the interim results from its paid pilot agreement with Obstetrix Medical Group.
The companies put pen to paper in mid-May to evaluate the functionality and suitability of the HeraCARE platform.
HeraCARE is an at-home digital pregnancy monitoring platform that is designed to improve prenatal and postnatal care.
These interim results were positive with an 89 per cent overall positive patient adherence rate achieved.
Furthermore, 100 per cent of the professional care team indicated HeraCARE is safe and effective and would recommend it to other care teams.
Upon completion of the pilot agreement, HeraMED and Obstetrix will determine whether to enter a comprehensive agreement for wider deployment.
Shares in HeraMED last traded at 19 cents on October 12. The company has a $33.66 million market cap.